<DOC>
	<DOCNO>NCT00146276</DOCNO>
	<brief_summary>Primary Objective : - To analyse time tumor progression patient cystectomized locally advanced transitional cell carcinoma ( TCC ) bladder , suitable cisplatin-based chemotherapy ( i.e . postoperative reduce renal function , advanced age ) . Patients randomize receive either adjuvant gemcitabine immediately radical operation ( treatment arm A ) treatment ( control arm B ) . Patients control arm treat gemcitabine soon tumor progression become evident clinically and/or radiologically . Secondary Objectives : The secondary objective study : - Estimation time-specific survival probability irrespective cause death . - Assessment toxicity tolerability gemcitabine - Description survival experience patient control arm beyond time initiate chemotherapy . - Assessment quality life ( European Organization Research Treatment Cancer [ EORTC ] Quality Life Questionnaire [ QLQ ] -C30 ) . Study Design : This open-label , prospective , multicenter , randomize , control phase 3 two-arm study use gemcitabine single agent chemonaive cystectomy patient locally advance TCC bladder adjuvant setting . The patient receive follow treatment : Arm A ( treatment ) : gemcitabine 1250 mg/m2 intravenously week 2 week ( day 1 8 ) follow 1-week rest period . Repeat cycle day 22 . Maximum 6 cycle . Begin treatment 3 month radical operation ( within first 6 week recommend ) . Arm B ( control ) : No immediate post-surgery treatment . Watchful wait ; treatment conditionally case progression gemcitabine ( dose schedule arm A ) .</brief_summary>
	<brief_title>Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy Locally Advanced Bladder Cancer</brief_title>
	<detailed_description>Primary Objective : - To analyse time tumor progression patient cystectomized locally advanced TCC bladder , suitable cisplatin-based chemotherapy ( i.e . postoperative reduce renal function , advanced age ) . Patients randomize receive either adjuvant Gemcitabine immediately radical operation ( treatment arm A ) treatment ( control arm B ) . Patients control arm treat Gemcitabine soon tumor progression becomes evident clinically and/or radiologically . Secondary Objectives : The secondary objective study : - Estimation time-specific survival probability irrespective cause death . - Assessment toxicity tolerability Gemcitabine - Description survival experience patient control arm beyond time initiate chemotherapy . - Assessment quality life ( EORTC QLQ-C30 ) . Study Design : This open-label , prospective , multicenter , randomize , control phase 3 two-arm study use Gemcitabine single agent chemonaive cystectomy patient locally advance TCC bladder adjuvant setting . The patient receive follow treatment : Arm A ( treatment ) : Gemcitabine 1250 mg/m2 intravenously week 2 week ( day 1 8 ) follow 1-week rest period . Repeat cycle day 22 . Maximum 6 cycle . Begin treatment 3 month radical operation ( within first 6 week recommend ) . Arm B ( control ) : No immediate post-surgery treatment . Watchful wait ; treatment conditionally case progression Gemcitabine ( dose schedule arm A ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Status radical cystectomy transitional cell carcinoma bladder , stage pT3a , pT3b , pT4a and/or pN1 , pN2 ( 5 lymph node positive tumor ) [ International Union Against Cancer ( UICC ) criterion , 1997 ] . Transitional cell carcinoma may without squamous cell carcinoma and/or adenocarcinoma component . Complete tumor removal radical operation establish macroscopically microscopically ( R0 resection ) . Patients regarded inappropriate cisplatinbased chemotherapy ( i.e . impaired renal function least 30 ml/min calculate creatinine clearance serumcreatinine le 3.0 mg/dl , age &gt; 70 ) eligible study enrollment [ calculation creatinine clearance accord Cockcroft Gault formula ] . Decision leave investigator 's discretion . Patient prior history systemic chemotherapy regimen . Previous local intravesical adjuvant chemotherapy immunotherapy allow . Prior radiation therapy allow complete least 12 week enrollment study patient recover toxic effect . Performance status 60 high Karnofsky Scale . Patient compliance , mental state , geographic proximity allow adequate followup Adequate bone marrow reserve : white blood cell ( WBC ) count &gt; = 3.5 x 10^9/L , platelet &gt; = 100 x 10^9/L , hemoglobin &gt; = 10 g/dL ( &gt; = 6.2 mmol/L &gt; = 100 g/L ) . Adequate liver function bilirubin &lt; 1.25 time upper limit normal range ; alanine transaminase ( ALT ) aspartate transaminase ( AST ) &lt; 2.5 time normal upper limit . Males female least 18 year age consider fit gemcitabine chemotherapy . Signed informed consent patient . Tumor completely remove ( visible tumor enlarge lymph node leave positive margin microscopicallyR1 R2 resection ) Patient distant metastasis metastasis . Tumor stage pT4b 5 locoregional lymph node positive tumor . Adeno and/or squamous cell carcinoma bladder without transitional cell carcinoma component ( different response chemotherapy ) . Time interval radical cystectomy first day chemotherapy exceed 3 month patient enrol treatment arm . Serum creatinine &gt; = 3.0 mg/dl ( &gt; = 265 mmol/l ) Active infection ( discretion investigator ) . Serious concomitant systemic disorder incompatible study ( discretion investigator ) Patients history prior malignancy basal squamous cell carcinoma skin , situ carcinoma cervix incidental carcinoma prostate must clinically free disease least 5 year prior study entry . Use investigational agent month enrollment study . White blood cell ( WBC ) count &lt; 3.5 x 10^9/L platelet &lt; 100 x 10^9/L hemoglobin &lt; 10 g/dL ( &lt; 6.2 mmol/L &lt; 100 g/L ) . Bilirubin &gt; = 1.25 time upper limit normal range ; alanine transaminase ( ALT ) aspartate transaminase ( AST ) &gt; = 2.5 time upper limit normal range</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>bladder cancer</keyword>
	<keyword>cystectomy</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>adjuvant chemotherapy</keyword>
	<keyword>locally advanced bladder cancer</keyword>
</DOC>